XML 26 R13.htm IDEA: XBRL DOCUMENT
v3.23.2

Goodwill and Intangible Assets | 6 Months Ended
--- | ---
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | Goodwill and Intangible Assets The following sets forth the goodwill and intangible assets by major asset class:
|  |  | June 30, 2023 |  | December 31, 2022
| Weighted Average Useful Life (Yrs) | Gross |  | Accumulated Amortization |  | Impairment |  | Net Book Value |  | Gross |  | Accumulated Amortization |  | Net Book Value
Indefinite lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  | $ | 10,513,371 |  |  | $ | — |  |  |  |  | $ | 10,513,371 |  |  | $ | 10,513,371 |  |  | $ | — |  |  | $ | 10,513,371 |
Definite lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licenses | 10 |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,323,761 |  |  | (1,323,761) |  |  | — |
Bioject(a) | 12 |  | 5,100,000 |  |  | (3,115,556) |  |  | (1,984,444) |  |  | — |  |  | 5,100,000 |  |  | (2,988,889) |  |  | 2,111,111 |
Other(b) | 18 |  | 4,050,000 |  |  | (4,050,000) |  |  | — |  |  | — |  |  | 4,050,000 |  |  | (4,031,250) |  |  | 18,750 |
Total intangible assets | 11 |  | 9,150,000 |  |  | (7,165,556) |  |  | (1,984,444) |  |  | — |  |  | 10,473,761 |  |  | (8,343,900) |  |  | 2,129,861 |
Total goodwill and intangible assets |  |  | $ | 19,663,371 |  |  | $ | (7,165,556) |  |  | $ | (1,984,444) |  |  | $ | 10,513,371 |  |  | $ | 20,987,132 |  |  | $ | (8,343,900) |  |  | $ | 12,643,232 |
(a)Bioject intangible assets represented the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition. (b)Other intangible assets represent the estimated fair value of acquired intellectual property. Aggregate amortization expense on intangible assets for the three and six months ended June 30, 2023 was $2.0 million and $2.1 million, respectively. Aggregate amortization expense on intangible assets for the three and six months ended June 30, 2022 was $131,000 and $257,000, respectively. During the three months ended June 30, 2023, the Company recorded an impairment charge of $2.0 million to research and development expense for the remaining intangible assets related to the Bioject acquisition, as it was determined that there are no current plans to develop or utilize this technology based on the latest Company strategy. There were no other impairment or impairment indicators present during the three and six months ended June 30, 2023. No losses were recorded during the three and six months ended June 30, 2022.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration